Abstract
Hepatocellular carcinoma (HCC) recurrence is one of the leading causes of death after orthotopic liver transplantation (OLT). The sixth complement component (C6) is a late-acting complement protein that participates in the assembly of the membrane attack complex, which has an indispensable role in innate and acquired immune responses, as well as cancer immune surveillance. However, studies assessing the association between C6 and HCC recurrence after OLT are scarce. This study aimed to evaluate the association of donor and recipient C6 single-nucleotide polymorphisms with the risk for HCC recurrence after OLT. A total of 71 adult patients who underwent primary LT for HCC were enrolled. HCC recurrence was observed in 26 (36.6%) patients. Ten single-nucleotide polymorphisms were genotyped and analyzed in both donor and recipient groups. Patients with the rs9200 heterozygous GA variant presented significantly higher HCC recurrence rates (54.17 vs 27.66%, P=0.028), and lower cumulative tumor-free survival and overall survival (P=0.006 and P=0.013, respectively) compared with those harboring the GG/AA genotype, in multivariate logistic regression and Cox regression analyses. The rs9200 heterozygous GA variant in C6 persisted as a statistically independent prognostic factor (P<0.05) for predicting HCC recurrence after OLT. In conclusion, recipient C6 rs9200 polymorphism is associated with HCC recurrence after OLT, and improves the predictive value of clinical models.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Parkin DM, Bray F, Ferlay J, Pisani P . Estimating the world cancer burden: Globocan 2000. Int J Cancer 2001; 94: 153–156.
El-Serag HB, Rudolph KL . Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007; 132: 2557–2576.
Tang ZY, Ye SL, Liu YK, Qin LX, Sun HC, Ye QH et al. A decade’s studies on metastasis of hepatocellular carcinoma. J Cancer Res Clin Oncol 2004; 130: 187–196.
Zimmerman MA, Ghobrial RM, Tong MJ, Hiatt JR, Cameron AM, Hong J et al. Recurrence of hepatocellular carcinoma following liver transplantation: a review of preoperative and postoperative prognostic indicators. Arch Surg 2008; 143: 182–188.
Sumie S, Kuromatsu R, Okuda K, Ando E, Takata A, Fukushima N et al. Microvascular invasion in patients with hepatocellular carcinoma and its predictable clinicopathological factors. Ann Surg Oncol 2008; 15: 1375–1382.
Parfitt JR, Marotta P, Alghamdi M, Wall W, Khakhar A, Suskin NG et al. Recurrent hepatocellular carcinoma after transplantation: use of a pathological score on explanted livers to predict recurrence. Liver Transpl 2007; 13: 543–551.
Tsoulfas G, Kawai T, Elias N, Ko SC, Agorastou P, Cosimi AB et al. Long-term experience with liver transplantation for hepatocellular carcinoma. J Gastroenterol 2011; 46: 249–256.
Mazzaferro V, Llovet JM, Miceli R, Bhoori S, Schiavo M, Mariani L et al. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol 2009; 10: 35–43.
Chan DL, Alzahrani NA, Morris DL, Chua TC . Systematic review of efficacy and outcomes of salvage liver transplantation after primary hepatic resection for hepatocellular carcinoma. J Gastroenterol Hepatol 2014; 29: 31–41.
Nagai S, Yoshida A, Facciuto M, Moonka D, Abouljoud MS, Schwartz ME et al. Ischemia time impacts recurrence of hepatocellular carcinoma after liver transplantation. Hepatology 2015; 61: 895–904.
Yan J, Tan C, Gu F, Jiang J, Xu M, Huang X et al. Sorafenib delays recurrence and metastasis after liver transplantation in a rat model of hepatocellular carcinoma with high expression of phosphorylated extracellular signal-regulated kinase. Liver Transpl 2013; 19: 507–520.
Mathur A, Franco ES, Leone JP, Osman-Mohamed H, Rojas H, Kemmer N et al. Obesity portends increased morbidity and earlier recurrence following liver transplantation for hepatocellular carcinoma. HPB (Oxford) 2013; 15: 504–510.
Wang P, Song W, Li H, Wang C, Shi B, Guo W et al. Association between donor and recipient smoothened gene polymorphisms and the risk of hepatocellular carcinoma recurrence following orthotopic liver transplantation in a Han Chinese population. Tumour Biol 2015; 36: 7807–7815.
Xu X, Ling Q, Wang J, Xie H, Wei X, Lu D et al. Donor miR-196a-2 polymorphism is associated with hepatocellular carcinoma recurrence after liver transplantation in a Han Chinese population. Int J Cancer 2015; 138: 620–629.
Nicholson-Weller A, Halperin JA . Membrane signaling by complement C5b-9, the membrane attack complex. Immunol Res 1993; 12: 244–257.
Wang C, Bozza PT, Barbashov SF, Sauty A, Nicholson-Weller A . In vitro and in vivo responses of murine granulocytes to human complement-derived, haemolytically inactive C5b67 (iC5b67). Clin Exp Immunol 1999; 117: 261–268.
Wurzner R, Orren A, Lachmann PJ . Inherited deficiencies of the terminal components of human complement. Immunodefic Rev 1992; 3: 123–147.
Ramaglia V, King RH, Nourallah M, Wolterman R, de Jonge R, Ramkema M et al. The membrane attack complex of the complement system is essential for rapid Wallerian degeneration. J Neurosci 2007; 27: 7663–7672.
Oka R, Sasagawa T, Ninomiya I, Miwa K, Tanii H, Saijoh K . Reduction in the local expression of complement component 6 (C6) and 7 (C7) mRNAs in oesophageal carcinoma. Eur J Cancer 2001; 37: 1158–1165.
Piao C, Cai L, Qiu S, Jia L, Song W, Du J . Complement 5a enhances hepatic metastases of colon cancer via monocyte chemoattractant protein-1-mediated inflammatory cell infiltration. J Biol Chem 2015; 290: 10667–10676.
Narayanasamy A, Ahn JM, Sung HJ, Kong DH, Ha KS, Lee SY et al. Fucosylated glycoproteomic approach to identify a complement component 9 associated with squamous cell lung cancer (SQLC). J Proteomics 2011; 74: 2948–2958.
Gabriel S, Ziaugra L, Tabbaa D . SNP genotyping using the Sequenom MassARRAY iPLEX platform. Curr Protoc Hum Genet 2009; Chapter 2: Unit 2.12.
Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996; 334: 693–699.
Morgan BP, Marchbank KJ, Longhi MP, Harris CL, Gallimore AM . Complement: central to innate immunity and bridging to adaptive responses. Immunol Lett 2005; 97: 171–179.
Pio R, Corrales L, Lambris JD . The role of complement in tumor growth. Adv Exp Med Biol 2014; 772: 229–262.
Cragg MS, Glennie MJ . Antibody specificity controls in vivo effector mechanisms of anti-CD20 reagents. Blood 2004; 103: 2738–2743.
Kolev M, Towner L, Donev R . Complement in cancer and cancer immunotherapy. Arch Immunol Ther Exp (Warsz) 2011; 59: 407–419.
Jurianz K, Ziegler S, Garcia-Schüler H, Kraus S, Bohana-Kashtan O, Fishelson Z et al. Complement resistance of tumor cells: basal and induced mechanisms. Mol Immunol 1999; 36: 929–939.
Halme J, Sachse M, Vogel H, Giese T, Klar E, Kirschfink M . Primary human hepatocytes are protected against complement by multiple regulators. Mol Immunol 2009; 46: 2284–2289.
Zhang S, Shan C, Cui W, You X, Du Y, Kong G et al. Hepatitis B virus X protein protects hepatoma and hepatic cells from complement-dependent cytotoxicity by up-regulation of CD46. FEBS Lett 2013; 587: 645–651.
Miura I, Graziano SL, Cheng JQ, Doyle LA, Testa JR . Chromosome alterations in human small cell lung cancer: frequent involvement of 5q. Cancer Res 1992; 52: 1322–1328.
Van den Berghe H, Le Beau M, Bernheim A . Fourth international workshop on chromosomes in leukemia 1982: deletion of 5q. Cancer Genet Cytogenet 1984; 11: 296–299.
Wieland I, Bohm M . Frequent allelic deletion at a novel locus on chromosome 5 in human lung cancer. Cancer Res 1994; 54: 1772–1774.
DiScipio RG, Hugli TE . The molecular architecture of human complement component C6. J Biol Chem 1989; 264: 16197–16206.
Westra D, Kurvers RA, van den Heuvel LP, Würzner R, Hoppenreijs EP, van der Flier M et al. Compound heterozygous mutations in the C6 gene of a child with recurrent infections. Mol Immunol 2014; 58: 201–205.
Leonardi GC, Candido S, Cervello M, Nicolosi D, Raiti F, Travali S et al. The tumor microenvironment in hepatocellular carcinoma (review). Int J Oncol 2012; 40: 1733–1747.
Acknowledgements
This study was partly supported by a grant from the National Natural Science Foundation of China (81370579) and the Science and Technology Commission of Shanghai Municipality, China (134119a6300).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Wang, Z., Liao, J., Wu, S. et al. Recipient C6 rs9200 genotype is associated with hepatocellular carcinoma recurrence after orthotopic liver transplantation in a Han Chinese population. Cancer Gene Ther 23, 157–161 (2016). https://doi.org/10.1038/cgt.2016.7
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/cgt.2016.7
This article is cited by
-
Identification and validation of a novel nine-gene prognostic signature of stem cell characteristic in hepatocellular carcinoma
Journal of Applied Genetics (2024)